Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$12.02
-0.3%
$10.87
$7.80
$28.09
$655.81MN/A579,529 shs264,410 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$19.42
+3.3%
$14.88
$6.53
$26.40
$169.93M0.1599,175 shs55,892 shs
Organogenesis stock logo
ORGO
Organogenesis
$5.00
-0.7%
$4.59
$2.45
$6.71
$633.67M1.751.40 million shs317,704 shs
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$14.36
-6.4%
$14.62
$6.43
$29.74
$524.14M0.73192,392 shs128,748 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
+0.50%+1.26%+6.16%+4.87%+1,205,999,900.00%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
+1.62%-1.00%+31.65%+128.43%+14.68%
Organogenesis stock logo
ORGO
Organogenesis
+1.41%-1.76%+11.04%+66.01%+86.30%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
+2.06%-8.63%+6.38%+21.25%-27.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$12.02
-0.3%
$10.87
$7.80
$28.09
$655.81MN/A579,529 shs264,410 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$19.42
+3.3%
$14.88
$6.53
$26.40
$169.93M0.1599,175 shs55,892 shs
Organogenesis stock logo
ORGO
Organogenesis
$5.00
-0.7%
$4.59
$2.45
$6.71
$633.67M1.751.40 million shs317,704 shs
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$14.36
-6.4%
$14.62
$6.43
$29.74
$524.14M0.73192,392 shs128,748 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
+0.50%+1.26%+6.16%+4.87%+1,205,999,900.00%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
+1.62%-1.00%+31.65%+128.43%+14.68%
Organogenesis stock logo
ORGO
Organogenesis
+1.41%-1.76%+11.04%+66.01%+86.30%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
+2.06%-8.63%+6.38%+21.25%-27.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3.00
Buy$32.25168.31% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.75
Reduce$73.67279.33% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.67
Moderate Buy$7.5050.15% Upside
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
3.00
Buy$29.50105.43% Upside

Current Analyst Ratings Breakdown

Latest MCRB, ORGO, BCAX, and RAPP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$41.00 ➝ $40.00
8/18/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$36.00
8/12/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$30.00
8/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$7.00 ➝ $9.00
8/6/2025
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$31.00
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$7.00
7/8/2025
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$28.00
(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/A$9.04 per shareN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.32M1.35N/AN/A$1.61 per share12.06
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.31$0.21 per share23.77$2.09 per share2.39
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/A$8.35 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$140K-$4.60N/AN/AN/AN/A-350.16%-67.69%11/12/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.14N/AN/AN/A-1.92%-0.37%-0.20%11/11/2025 (Estimated)
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$78.31M-$2.50N/AN/AN/AN/A-29.99%-28.64%11/6/2025 (Estimated)

Latest MCRB, ORGO, BCAX, and RAPP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.54-$0.50+$0.04-$0.50N/AN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
8/7/2025Q2 2025
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$0.87-$0.75+$0.12-$0.75N/AN/A
8/6/2025Q2 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$2.72-$2.27+$0.45-$2.27$11.75 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
25.80
25.80
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
1.57
1.57
Organogenesis stock logo
ORGO
Organogenesis
N/A
3.95
3.45
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A
22.75
22.75

Institutional Ownership

CompanyInstitutional Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
15.50%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
4.70%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
13.57%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3254.56 million46.11 millionN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.75 million8.34 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.86 million85.00 millionOptionable
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A36.50 million31.55 millionN/A

Recent News About These Companies

Analysts Offer Predictions for RAPP Q2 Earnings
Rapport (RAPP) Q2 Net Loss Widens 47%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bicara Therapeutics stock logo

Bicara Therapeutics NASDAQ:BCAX

$12.02 -0.04 (-0.33%)
Closing price 03:59 PM Eastern
Extended Trading
$12.05 +0.03 (+0.25%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$19.42 +0.62 (+3.30%)
Closing price 03:59 PM Eastern
Extended Trading
$19.36 -0.06 (-0.28%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$5.00 -0.04 (-0.70%)
Closing price 03:59 PM Eastern
Extended Trading
$5.00 +0.01 (+0.20%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Rapport Therapeutics stock logo

Rapport Therapeutics NASDAQ:RAPP

$14.36 -0.99 (-6.45%)
Closing price 03:59 PM Eastern
Extended Trading
$14.55 +0.19 (+1.32%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.